有スルコトヲ得

及品の保設有定

第五條

式見積の様

一　本條約第二條乃至第四條ニ規定セラルル各見積ハ常設中央委員會ニ依リ隨時定メラレ且同委員會ニ依リ國際聯盟ノ一切ノ聯盟國及第二十七條ニ掲ゲラルル非聯盟國ニ通知セラルル様式ニ從フベシ

の見内積容様式

二　各見積ニハ各國又ハ各領域ニ付及各年ニ付「アルカロイド」又ハ鹽類ノ形態ノモノタルト「アルカロイド」又ハ鹽類ノ製劑ノ形態ノモノタルトヲ問ハズ各藥品ニ關シ左記ヲ示スベシ

(イ)　醫療用及學術用ノ爲其レ自體トシテノ使用ニ必要ナル數量（内部消費ノ爲ノモノタルト輸出ノ爲ノモノタルトヲ問ハズ輸出スルニ輸出許可ヲ要セザル製劑ノ製造ニ必要ナル數量ヲ含ム）

(ロ)　内部消費ノ爲ノモノタルト輸出ノ爲ノモノタルトヲ問ハズ轉換用ニ必要ナル數量

(ハ)　保有セントスル準備在庫品ノ數量

serve stocks, create and maintain Government stocks.

ARTICLE 5.

1. Each estimate provided for in Articles 2 to 4 of this Convention shall be in the form from time to time prescribed by the Permanent Central Board and communicated by the Board to all the Members of the League of Nations and to the non-member States mentioned in Article 27.

2. Every estimate shall show for each country or territory for each year in respect of each of the drugs whether in the form of alkaloid or salts or of preparations of the alkaloid or salts:

(*a*) The quantity necessary for use as such for medical and scientific needs, including the quantity required for the manufacture of preparations for the export of which export authorisations are not required, whether such preparations are intended for domestic consumption or for export;

(*b*) The quantity necessary for the purpose of conversion, whether for domestic consumption or for export;

(*c*) The amount of the reserve stocks which it is desired to maintain;

(ニ) 第四條ニ規定セラルル政府在庫品ノ設定及保有ニ必要ナル數量

各國又ハ各領域ニ付テノ見積ノ總量ハ本號(イ)及(ロ)ニ掲ゲラルル數量ノ合計ニ準備在庫品及政府在庫品ヲ希望ノ平準ニ達セシムルニ必要ナルコトアルベキ數量ヲ加算シ又ハ右合計ヨリ此等在庫品ガ右平準ヲ超過スルコトアルベキ數量ヲ控除シタルモノヨリ成ルベシ但シ此等ノ加算又ハ控除ハ關係締約國ガ常設中央委員會ニ必要ナル見積ヲ適當ノ期間内ニ送付セルニ非ザル限リ考慮セラレザルベシ

三 各見積ニハ之ニ記載セラルル諸數量ガ計算セラレタル方法ノ説明書ヲ添附スベシ右數量ガ需要ノ有リ得ベキ變動ニ對スル餘裕ヲ包含スル樣計算セラレタルトキハ見積ニハ斯ク包含セラレタル餘裕量ヲ指示スルヲ要ス第二類ニ包含セラレ又ハ包含セラルルコトアルベキ何レカノ藥品ノ場合ニ於テハ他ノ藥品ノ場合ニ於ケルヨリ大ナル餘裕ノ必要ナルコトアリ得ルモノトス

四 各見積ハ其ノ關スル年ノ前年ノ八月一日以前ニ常設中央委員會ニ到達スルコトヲ要ス

出見積の説明書

出見積の提期日

(*d*) The quantity required for the establishment and maintenance of any Government stocks as provided for in Article 4.

The total of the estimates for each country or territory shall consist of the sum of the amounts specified under (*a*) and (*b*) of this paragraph with the addition of any amounts which may be necessary to bring the reserve stocks and the Government stocks up to the desired level, or after deduction of any amounts by which those stocks may exceed that level. These additions or deductions shall, however, not be taken into account except in far as the High Contracting Parties concerned shall have forwarded in due course the necessary estimates to the Permanent Gentral Board.

3. Every estimate shall be accompanied by a statement explaining the method by which the several amounts shown in it have been calculated. If these amounts are calculated so as to include a margin allowing for possible fluctuations in demand, the estimates must indicate the extent of the margin so included. It is understood that in the case of any of the drugs which are or may be included in Group II, a wider margin may be necessary than in the case of the other drugs.

4. Every estimate shall reach the Permanent Central Board not later than August 1st in the year preceding that

補足見積の提出期日

五　補足見積ハ其ノ完了後直ニ常設中央委員會ニ送付セラルベシ

監督機関による見積の検査

六　見積ハ監督機關ニ依リ檢査セラルベシ國際聯盟ノ阿片及他ノ危險藥品ノ取引ニ關スル諮問委員會、常設中央委員會、國際聯盟保健委員會竝ニ公衆衛生國際事務局ハ各右監督機關ノ一員ヲ任命スルノ權利ヲ有スベシ監督機關ノ事務局ハ國際聯盟事務總長ニ依リ設ケラルベク事務總長ハ常設中央委員會トノ密接ナル協力ヲ確保スベシ

監督機関の構成

監督機關ハ政府ノ需要ニ關スルモノヲ除キ見積ノ提出セラレタル國又ハ領域ニ關シ、該見積ヲ完全ナラシメ又ハ之ニ記載セラルル事項ヲ説明スル爲ニ其ノ必要ナリト認ムルコトアルベキ情報又ハ詳細ヲ更ニ要求スルヲ得ベク且斯クシテ得タル情報又ハ詳細ニ基キ關係政府ノ同意ヲ以テ見積ヲ修正スルコトヲ得第二類ニ包含セラレ又ハ包含セラルルコトアルベキ何レカノ藥品ノ場合ニ於テハ概略説明ニテ足ルモノトス

監督機関の権能

同上

七　提出セラレタル見積ノ監督機關ニ依ル前記第六號

in respect of which the estimate is made.

5. Supplementary estimates shall be sent to the Permanent Central Board immediately on their completion.

6. The estimates will be examined by a Supervisory Body. The Advisory Committee on the Traffic in Opium and other Dangerous Drugs of the League of Nations, the Permanent Central Board, the Health Committee of the League of Nations and the Office international d'Hygiène publique shall each have the right to appoint one member of this Body. The Secretariat of the Supervisory Body shall be provided by the Secretary-General of the League of Nations, who will ensure close collaboration with the Permanent Central Board.

The Supervisory Body may require any further information or details, except as regards requirements for Government purposes, which it may consider necessary, in respect of any country or territory on behalf of which an estimate has been furnished in order to make the estimate complete or to explain any statement made therein, and may, with the consent of the Government concerned, amend any estimate in accordance with any information or detail so obtained. It is understood that in the case of any of the drugs which are or may be included in Group II a summary statement shall be sufficient.

7. After examination by the Supervisory Body as provided

ニ規定セラルル檢査ノ後及見積ノ提出セラレザル各國又ハ各領域ニ付テノ見積ノ右機關ニ依ル第二條ニ規定セラルル決定ノ後監督機關ハ每年十一月一日以前ニ事務總長ヲ經由シ國際聯盟ノ一切ノ聯盟國及第二十七條ニ掲ゲラルル非聯盟國ニ各國又ハ各領域ニ付テノ見積ノ表ヽ監督機關ガ必要ナリト認ムル限リ前記第六號ニ從ヒ與ヘラレ又ハ要求セラレタル說明ノ要領及監督機關ガ右見積若ハ說明又ハ說明ノ要求ニ關シ其ノ表明セントト欲スルコトアルベキ意見ヲ送付スベシ

同上

八　年中ニ常設中央委員會ニ送付セラレタル各補足見積ハ前記第六號及第七號ニ掲ゲラルル手續ニ從ヒ監督機關ニ依リ遲滯ナク處理セラルルベシ

第三章　製造制限

第六條

麻藥の製造制限

一　何レノ國又ハ領域ニ於テモ一年間ニ於テ何レカノ藥品ノ數量ハ左記數量ノ合計ヲ超過シテ製造セラルル

in paragraph 6 above of the estimates furnished, and after the determination by that Body as provided in Article 2 of the estimates for each country or territory on behalf of which no estimates have been furnished, the Supervisory Body shall forward, not later than November 1st in each year, through the intermediary of the Secretary-General, to all the Members of the League of Nations and non-member States referred to in Article 27, a statement containing the estimates for each country or territory, and, so far as that Supervisory Body may consider necessary, an account of any explanations given or required in accordance with paragraph 6 above, and any observations which the Supervisory Body may desire to make in respect of any such estimate or explanation, or request for an explanation.

8. Every supplementary estimate sent to the Permanent Central Board in the course of the year shall be dealt with without delay by the Supervisory Body in accordance with the procedure specified in paragraphs 6 and 7 above.

Chapter III.—Limitation of Manufacture.

Article 6.

1. There shall not be manufactured in any country or territory in any one year a quantity of any of the drugs

ルコトナカルベシ

(イ) 右年ニ付テノ右ノ國又ハ領域ニ關スル見積ノ範圍内ニ於テ醫療用及學術用ノ爲其レ自體トシテノ使用ニ必要ナル數量（内部消費ノ爲ノモノタルトヲ問ハズ輸出スルニ輸出許可ヲ要セザル製劑ノ製造ニ必要ナル數量ヲ含ム）

(ロ) 右年ニ付テノ右ノ國又ハ領域ニ關スル見積ノ範圍内ニ於テ内部消費ノ爲ノモノタルトヲ問ハズ轉換ニ必要ナル數量

(ハ) 本條約ノ規定ニ依ル輸出ノ註文ヲ年内ニ履行スル爲右ノ國又ハ領域ガ必要トスルコトアルベキ數量

(ニ) 準備在庫品ヲ右年ニ付テノ見積ニ掲ゲラルル平準ニ維持スル爲右ノ國又ハ領域ガ必要トスルコトアルベキ數量

(ホ) 政府在庫品ヲ右年ニ付テノ見積ニ掲ゲラルル平準ニ維持スル爲必要トスルコトアルベキ數量

greater than the total of the following quantities:

（*a*） The quantity required within the limits of the estimates forthat country or territory for that year for use as such for its medical and scientific needs including the quantity required for the manufacture of preparations for the export of which export authorisations are not required, whether such preparations are intended for domestic consumption or for export;

（*b*） The quantity required within the limits of the estimates for that country or territory for that year for conversion, whether for domestic consumption or for export;

（*c*） Such quantity as may be required by that country or territory for the execution during the year of orders for export in accordance with the provisions of this Convention;

（*d*） The quantity, if any, required by that country or territory for the purpose of maintaining the reserve stocks at the level specified in the estimates for that year;

（*e*） The quantity, if any, required for the purpose of maintaining the Government stocks at the level

二　製造セラレタル數量ガ前記數量ノ合計ヨリ第七條第一項ニ依ル控除ヲ爲シテ得タル數量ヲ超過スルコトヲ締約國ガ年末ニ於テ發見スルトキハ右超過量ハ翌年中ニ製造セラルベキ數量ヨリ控除セラルベキモノトス締約國ハ常設中央委員會ニ自國ノ年次統計ヲ送付スルニ當リ右超過ノ理由ヲ示スベシ

超過量に対する措置

第七條

第六條ニ依リ何レカノ國又ハ領域ニ於テ一年間ニ製造セラルルコトヲ許サルル各藥品ノ總量ヨリ左記數量ヲ控除スベシ

(一)　返還セラレタルモノヲ含ム輸入藥品ノ數量ヨリ再輸出量ヲ控除シテ得タル數量

(二)　押收セラレタル藥品ニシテ其レ自體トシテ內部消費ノ爲又ハ轉換ノ爲ニ利用セラルルモノノ數量

當該年中ニ前記控除ノ何レカヲ爲シ得ザルトキハ年末ニ於テ殘存スル超過數量ハ翌年ノ見積ヨリ控除セラルベシ

数れら造各る控總量品製ベ除量かさ

specified in the estimates for that year.

2. It is understood that, if at the end of any year, any High Contracting Party finds that the amount manufactured exceeds the total of the amounts specified adove, less any deductions made under Article 7, paragraph 1, such excess shall be deducted from the amount to be manufactured during the following year. In forwarding their annual statistics to the Permanent Central Board, the High Contracting Parties shall give the reasons for any such excess.

Article 7.

There shall be deducted from the total quantity of each drug permitted under Article 6 to be manufactured in any country or territory during any one year:

(i) Any amounts of that drug imported including any returned deliveries of the drug, less quantities re-exported.

(ii) Any amounts of the drug seized and utilised as such for domestic consumption or for conversion.

If it should be impossible to make any of the above deductions during the course of the current year, any amounts remaining in excess at the end of the year shall be deducted from the estimates for the following year.

見積に従い転換の目的のため輸入され又は製造される薬品の全数量利用

残存部分の見積からの控除

在庫品の超過量

第八條

何レカノ國又ハ領域ニ付テノ見積ニ從ヒ轉換ノ目的ノ爲該國又ハ該領域ニ於テ輸入セラレ又ハ製造セラルル何レカノ藥品ノ數量ハ可能ナルトキハ右見積ノ適用セラルル期間内ニ右目的ノ爲全部利用セラルベシ

尤モ右期間内ニ右目的ノ爲全數量ヲ利用スルコト不可能ナル場合ニハ年末ニ於テ利用セラレズシテ殘存スル部分ハ翌年ニ付テノ右ノ國又ハ領域ニ關スル見積ヨリ控除セラルベシ

第九條

本條約ノ一切ノ規定ガ實施セラレタル際何レカノ國又ハ領域ニ於ケル何レカノ藥品ノ其ノ當時ノ現存在庫品ガ該國又ハ該領域ニ付テノ見積ニ依リ保有セント欲スル該藥品ノ準備在庫品ノ數量ヲ超過スルトキハ該超過量ハ當該年中ニ於テ本條約ノ規定ニ依リ場合ニ應ジ通常輸入セラレ又ハ製造セラルベキ數量ヨリ控除セラルベシ

右ニ依ラザルトキハ本條約ノ一切ノ規定ガ實施セラレ

Article 8.

The full amount of any of the drugs imported into or manufactured in any country or territory for the purpose of conversion in accordance with the estimates for that country or territory shall, if possible, be utilised for that purpose within the period for which the estimate applies.

In the event, however, of it being impossible to utilise the full amount for that purpose within the period in question, the portion remaining unused at the end of the year shall be deducted from the estimates for that country or territory for the following year.

Article 9.

If at the moment when all the provisions of the Convention shall have come into force, the then existing stocks of any of the drugs in any country or territory exceeds the amount of the reserve stocks of that drug, which according to the estimates for that country or territory, it is desired to maintain, such excess shall be deducted from the quantity which, during the year, could ordinarily be imported or manufactured as the case may be under the provisions of this Convention.

Alternatively, the excess stocks existing at the moment

タル際現存スル超過在庫品ハ政府ニ依リ保管セラルベク且本條約ニ適合スベキ數量ニ於テノミ隨時交付セラルベシ何レカノ年中ニ於テ斯ク交付セラレタル數量ハ該年中場合ニ應ジ製造セラレ又ハ輸入セラルベキ總量ヨリ控除セラルベシ

when all the provisions of the Convention shall have come into force shall be taken possession of by the Government and released from time to time in such quantities only as may be in conformity with the present Convention. Any quantities so released during any year shall be deducted from the total amount to be manufactured or imported as the case may be during that year.

第四章　禁止及制限

CHAPTER IV.—PROHIBITIONS AND RESTRICTIONS

第十條

ARTICLE 10.

輸出禁止の製剤

一　締約國ハ「ヂアセチルモルヒネ」其ノ鹽類及「ヂアセチルモルヒネ」又ハ其ノ鹽類ヲ含有スル製剤ノ其ノ領域ヨリノ輸出ヲ禁止スベシ

1. The High Contracting Parties shall prohibit the export from their territories of diacetylmorphine, its salts, and preparations containing diacetylmorphine, or its salts.

輸出許可の右製剤

二　尤モ締約國ハ「ヂアセチルモルヒネ」ノ製造セラレザル國ノ政府ヨリ請求ヲ受クルトキハ該國ノ醫療用及學術用ニ必要ナル「ヂアセチルモルヒネ」其ノ鹽類及「ヂアセチルモルヒネ」又ハ其ノ鹽類ヲ含有スル製劑ノ數量ノ該國ヘノ輸出ヲ許可スルコトヲ得但シ右請求ハ輸入證明書ヲ伴ヒ且該證明書ニ指示セラルル官廳ニ仕向ケラルルコトヲ要ス

2. Nevertheless, on the receipt of a request from the Government of any country in which diacetylmorphine is not manufactured, any High Contracting Party may authorise the export to that country of such quantities of diacetylmorphine, its salts, and preparations containing diacetylmorphine or its salts, as are necessary for the medical and scientific needs of that country, provided that the request is accompanied by an import certificate and is consigned to the Government Department indicated in the certificate.

右製劑輸

三　斯ク輸入セラレタル數量ハ輸入國政府ニ依リ其ノ

3. Any quantities so imported shall be distributed by and

入の際の分配

取引又は取引のための製造の制限される製産品

右製産品取引又は取引のための製造の許可国の通知義務

責任ニ於テ分配セラルベシ

第十一條

一　阿片ノ「フェナントレン」、アルカロイド」又ハ「コカ」葉ノ「エクゴニン」、アルカロイド」ヨリ得タル製産品ニシテ本日醫療用又ハ學術用ニ使用セラレザルモノノ取引又ハ取引ノ爲ノ製造ハ該製産品ノ醫療的又ハ學術的價値アルコトガ關係政府ノ滿足シ得ル程度ニ確認セラルルニ非ザレバ何レノ國又ハ領域ニ於テモ行ハレザルベシ

右ノ場合ニ於テハ（政府ニ於テ右製産品ガ中毒癖ヲ生ゼシメ得ザルカ又ハ中毒癖ヲ生ゼシメ得ル製産品ニ轉換セラレ得ザルコトヲ決定スルニ非ザレバ）製造ヲ許サルル數量ハ後ニ揭ゲラルル決定アル迄醫療用及學術用ノ爲ノ右ノ國又ハ領域ノ内部需要量ノ合計竝ニ輸出註文ニ應ズルニ必要ナル數量ヲ超過セザルベク且本條約ノ規定ガ適用セラルベシ

二　右製産品ノ取引又ハ取引ノ爲ノ製造ヲ開始スルコトヲ許ス締約國ハ其ノ旨ヲ國際聯盟事務總長ニ直ニ通告スベク事務總長ハ他ノ締約國及聯盟保健委員會ニ之ヲ通知スベシ

on the responsibility of the Government of the importing country.

Article 11.

1. No trade in or manufacture for trade of any product obtained from any of the phenanthrene alkaloids of opium or from the ecgonine alkaloids of the coca leaf, not in use on this day's date for medical or scientific purposes shall take place in any country or territory unless and until it has been ascertained to the satisfaction of the Government concerned that the product in question is of medical or scientific value.

In this case (unless the Government determines that such product is not capable of producing addiction or of conversion into a product capable of producing addiction) the quantities permitted to be manufactured, pending the decision hereinafter referred to, shall not exceed the total of the domestic requirements of the country or territory for medical and scientific needs, and the quantity required for export orders and the provisions of this Convention shall apply.

2. Any High Contracting Party permitting trade in or manufacture for trade of any such product to be commenced shall immediately send a notification to that effect to the Secretary-General of the League of Nations, who shall advise the

右製産品に関する保健委員会の審査決定

三　依テ保健委員會ハ公衆衛生國際事務局常設委員會ニ諮問シタル後右製産品ガ中毒癖ヲ生ゼシメ得ルモノ（其ノ結果トシテ第一類ノ亞類(イ)ニ掲ゲラルル藥品ト看做サレ得ルモノ）ナルカ又ハ斯ル藥品ニ轉換シ得ルモノ（其ノ結果トシテ第一類ノ亞類(ロ)又ハ第二類ニ掲ゲラルル藥品ト看做サレ得ルモノ）ナルカヲ決定スベシ

同上

四　保健委員會ニ於テ右製産品ガ其レ自體トシテ中毒癖ヲ生ゼシメ得ル藥品ニ非ザルモ斯ル藥品ニ轉換シ得ルコトヲ決定スル場合ニ於テハ該藥品ガ第一類ノ亞類(ロ)又ハ第二類ノ何レニ屬スベキヤノ問題ハ其ノ科學的及技術的方面ノ檢査ヲ爲シ得ル三名ノ專門家委員會ニ決定ノ爲付託セラルベク右專門家ノ內一名ハ關係政府ニ依リ選任セラレ一名ハ聯盟阿片諮問委員會ニ依リ選任セラレ他ノ一名ハ斯ク選任セラレタル二人ニ依リ選任セラルベシ

同上決定の通知

五　前二號ニ從ヒ到達シタル決定ハ國際聯盟事務總長ニ通告セラルベク事務總長ハ之ヲ一切ノ聯盟國及第二十七條ニ掲ゲラルル非聯盟國ニ通知スベシ

other High Contracting Parties and the Health Committee of the League.

3. The Health Committee will thereupon, after consulting the Permanent Committee of the Office international d'Hygiène publique, decide whether the product in question is capable of producing addiction (and is in consequence assimilable to the drugs mentioned in sub-group (*a*) of Group I), or whether it is convertible into such a drug (and is in consequence assimilable to the drugs mentioned in sub-group (*b*) of Group I or in Group II).

4. In the event of the Health Committee deciding that the product is not itself a drug capable of producing addiction, but is convertible into such a drug, the question whether the drug in question shall fall under sub-group (*b*) of Group I or under Group II shall be referred for decision to a body or three experts competent to deal with the scientific and technical aspects of the matter, of whom one member shall be selected by the Government concerned, one by the Opium Advisory Committee of the League, and the third by the two members so selected.

5. Any decisions arrived at in accordance with the two preceding paragraphs shall be notified to the Secretary-General of the League of Nations, who will communicate it to all the

六　右決定ニシテ右製産品ガ中毒癖ヲ生ゼシメ得ルカ又ハ中毒癖ヲ生ゼシメ得ル藥品ニ轉換シ得ルモノナリトスルトキハ締約國ハ事務總長ヨリ其ノ旨ノ通知ヲ受領シタル上右藥品ニ對シ其ノ第一類又ハ第二類ノ何レニ屬スルカニ從ヒ本條約ニ定メラルル適當ナル制度ヲ適用スベシ

措置に関する同上の決定

七　何レカノ締約國ニ依リ事務總長ニ宛テラルル要求ニ基キ右決定ハ更ニ得タル經驗ニ照シ前記手續ニ從ヒ變更セラルルコトヲ得

同上の決定の変更

第十二條

一　何レカノ藥品ノ締約國ノ領域ヘノ輸入又ハ該領域ヨリノ輸出ハ本條約ノ規定ニ從フニ非ザレバ行ハレザルベシ

輸出入又は輸入に関する条約の規定に従わない藥品の輸出入又は輸入の禁止

二　何レカノ藥品ノ何レカノ國又ハ領域ヘノ一年間ニ於ケル輸入ハ第五條ニ定メラルル見積ト該年中該國又ハ該領域ヨリ輸出セラルル數量トノ合計ヨリ該年中該國又ハ該領域ニ於テ製造セラルル數量ヲ控除シ

Members of the League and to the non-member States mentioned in Article 27.

6. If the decisions are to the effect that the product in question is capable of producing addiction or is convertible into a drug capable of producing addiction, the High Contracting Parties will, upon receipt of the communication from the Secretary-General, apply to the drug the appropriate régime laid down in the present Convention according as to whether it falls under Group I or under Group II.

7. Any such decision may be revised, in accordance with the foregoing procedure, in the light of further experience, on an application addressed by any High Contracting Party to the Secretary-General.

Article 12.

1. No import of any of the drugs into the territories of any High Contracting Party or export from those territories shall take place except in accordance with the provisions this Convention.

2. The imports in any one year into any country or territory of any of the drugs shall not exceed the total of the estimates as defined in Article 5 and of the amount exported from that country or territory during the year, less the

テ得タル數量ヲ超過セザルベシ

第五章　取締

第十三條

一　(イ)　締約國ハ「ジュネーヴ」條約第四條ニ掲ゲラルル物質ニ適用セラルル同條約ノ規定（又ハ之ニ合致スル規定）ヲ第一類ニ於ケル一切ノ藥品ニ適用スベシ締約國ハ又右規定ヲ「ジュネーヴ」條約第四條ニ包含セラルル「モルヒネ」及「コカイン」ノ製劑竝ニ第一類ニ於ケル他ノ藥品ノ一切ノ製劑ニ適用スベシ但シ「ジュネーヴ」條約第八條ニ依リ同條約ノ規定ヨリ除外セラルルコトアルベキ製劑ハ之ヲ除ク

(ロ)　締約國ハ液體又ハ固體タル無力ノ物質中ニ於ケル「モルヒネ」「コカイン」又ハ其ノ鹽類ノ溶液又ハ稀薄物ニシテ「モルヒネ」〇・二「パーセント」以下又ハ「コカイン」〇・一「パーセント」以下ヲ含有スルモノヲ右割合ヲ超エテ含有スル製劑ト同樣ニ取扱フベシ

二　締約國ハ第二類ニ包含セラレ又ハ包含セラルルコトアルベキ藥品ニ對シ左記「ジュネーヴ」條約

同　上

amount manufactured in that country or territory in that year.

Chapter V.—Control.

Article 13.

1. (*a*) The High Contracting Parties shall apply to all the drugs in Group I the provisions of the Geneva Convention which are thereby applied to substances specified in its fourth Article (or provisions in conformity therewith). The High Contracting Parties shall also apply these provisions to preparations made from morphine and cocaine and covered by Article 4 of the Geneva Convention and to all other preparations made from the other drugs in Group I except such preparations as may be exempted from the provisions of the Geneva Convention under its eighth Article.

(*b*) The High Contracting Parties shall treat solutions or dilutions of morphine or cocaine or their salts in an inert substance, liquid or solid, which contain 0.2 per cent or less of morphine or 0.1 per cent or less of cocaine in the same way as preparations containing more than these percentages.

2. The High Contracting Parties shall apply to the drugs which are or may be included in Group II the following pro-

visions of the Geneva Convention (or provisions in conformity therewith):

(*a*) The provisions of Articles 6 and 7 in so far as they relate to the manufacture, import, export and wholesale trade in those drugs;

(*b*) The provisions of Chapter V, except as regards compounds containing any of these drugs which are adapted to a normal therapeutic use;

(*c*) The provisions of paragraphs 1 (*b*), (*c*) and (*e*) and paragraph 2 of Article 22, provided:

(i) That the statistics of import and export may be sent annually instead of quarterly, and

(ii) That paragraph 1 (*b*) and paragraph 2 of Article 22 shall not apply to preparations containing any of these drugs.

ARTICLE 14.

1. Any Government which has issued an authorisation for the export of any of the drugs which are or may be included in Group I to any country or territory to which neither this Convention nor the Geneva Convention applies shall immediately notify the Permanent Central Board of the issue of

ノ規定（又ハ之ニ合致スル規定）ヲ適用スベシ

(ｲ) 第六條及第七條ノ規定ガ右藥品ノ製造、輸入、輸出及卸賣ニ關スル限リ該規定

(ﾛ) 第五章ノ規定但シ右藥品ノ何レカヲ含有スル合成物ニシテ普通ノ治療用ニ充テラルルモノニ付テハ之ヲ適用セズ

(ﾊ) 第二十二條第一號(ﾛ)、(ﾊ)及(ﾎ)竝ニ第二號ノ規定但シ

(一) 輸入及輸出ノ統計ハ毎四半期ノ代ニ一年毎ニ送付セラレ得ベク

(二) 第二十二條第一號(ﾛ)及第二號ハ右藥品ノ何レカヲ含有スル製劑ニ適用セラレザルベシ

第十四條

一 第一類ニ包含セラレ又ハ包含セラルルコトアルベキ藥品ノ本條約及「ジュネーヴ」條約ノ何レモ適用セラレザル國又ハ領域ヘノ輸出ニ對シ許可證ヲ發給シタル政府ハ許可證ノ發給ヲ直ニ常設中央委員會ニ通告スベシ但シ輸出ノ請求ガ五キログラム以上ナルヘ央ル給許
の委常に可
通員設関証
告会中寸発

トキハ右輸出ガ輸入スル國又ハ領域ニ付テノ見積ノ超過ヲ生ゼシメザルコトヲ右政府ニ於テ常設中央委員會ヨリ確ムル迄許可證ハ發給セラレザルベキモノトス常設中央委員會ガ右超過ノ生ズベキ旨ノ通告ヲ發スルトキハ政府ハ右超過ヲ生ゼシムベキ數量ノ輸出ヲ許可セザルベシ

常設中央委員会の超過量に関する通告

二　常設中央委員會ニ提出セラレタル輸入及輸出ノ報告ニ依リ又ハ前號ニ從ヒ同委員會ニ爲サレタル通告ニ依リ何レカノ國又ハ領域ニ輸出セラレ又ハ輸出ノ許可セラレタル數量ガ第五條ニ定メラルル該國又ハ該領域ニ付テノ見積ノ總量ト輸出セラレタルコトノ判明セル數量トノ和ヲ超過スト認メラルルトキハ同委員會ハ直ニ右事實ヲ一切ノ締約國ニ通告スベク締約國ハ該年中右ノ國又ハ領域ニ對シ更ニ輸出ヲ許可セザルベシ但シ左記ノ場合ハ此ノ限ニ在ラズ

(一)　補足見積ガ過剩輸入數量及所要追加數量ニ關シ提出セラルル場合又ハ

(二)　輸出國ノ政府ニ於テ輸出ガ人道ノ爲又ハ患者ノ治療ノ爲缺クベカラザルモノト認ムル例外的場合

the authorisation; provided that, if the request for export amounts to 5 kilogrammes or more, the authorisation shall not be issued until the Government has ascertained from the Permanent Central Board that the export will not cause the estimates for the importing country or territory to be exceeded. If the Permanent Central Board sends a notification that such an excess would be caused, the Government will not authorise the export of any amount which would have that effect.

2. If it appears from the import and export returns made to the Permanent Central Board of from the notifications made to the Board in pursuance of the preceding paragraph that the quantity exported or authorised to be exported to any country or territory exceeds the total of the estimates for that country or territory as defined in Article 5, with the addition of the amounts shown to have been exported, the Board shall immediately notify the fact to all the High Contracting Parties, who will not, during the currency of the year in question, authorise any new exports to that country except:

(i) In the event of a supplementary estimate being furnished for that country in respect both of any quantity over-imported and of the additional quantity required; or

(ii) In exceptional cases where the export in the opinion of the Government of the exporting country is es-

三　常設中央委員會ハ毎年各國又ハ各領域ニ關シ前年ニ付左記ヲ示ス表ヲ作成スベシ

(イ)　各藥品ニ關スル見積
(ロ)　各藥品ノ消費數量
(ハ)　各藥品ノ製造數量
(ニ)　各藥品ノ轉換數數量
(ホ)　各藥品ノ輸入數數量
(ヘ)　各藥品ノ輸出數數量
(ト)　輸出スルニ輸出許可ヲ要セザル製劑ノ製造ニ使用セラレタル各藥品ノ數量

右表ガ何レカノ締約國ノ本條約ニ依ル義務ヲ履行セザリシカ又ハ履行セザリシコトアルベキコトヲ示ストキハ右委員會ハ國際聯盟事務總長ヲ通ジ右締約國ヨリ說明ヲ求ムルノ權利ヲ有スベク此ノ場合ニハ「ジュネーヴ」條約第二十四條第二號乃至第七號ニ掲ゲラルル手續ハ適用セラルベシ

右委員會ハ爾後能フ限リ速ニ前記ノ表、委員會ガ不必要ナリト思考セザル限リ前項ニ從ヒ與ヘラレタル又ハ

sential in the interests of humanity or for the treatment of the sick.

3. The Permanent Central Board shall each year prepare a statement showing, in respect of each country or territory for the preceding year;

(*a*) The estimates in respect of each drug;
(*b*) The amount of each drug consumed;
(*c*) The amount of each drug manufactured;
(*d*) The amount of each drug converted;
(*e*) The amount of each drug imported;
(*f*) The amount of each drug exported;
(*g*) The amount of each drug used for the compounding of preparations, exports of which do not require export authorisations.

If such statement indicates that any High Contracting Party has or may have failed to carry out his obligations under this Convention, the Board shall have the right to ask for explanations, through the Secretary-General of the League of Nations, from that High Contracting Party, and the procedure specified in paragraphs 2 to 7 of Article 24 of the Geneva Convention shall apply in any such case.

The Board shall, as soon as possible thereafter, publish the statement above mentioned together with an account, unless

要求セラレタル説明ノ要領及右ノ説明又ハ説明ノ要求ニ關シ其ノ表明セント欲スルコトアルベキ意見ヲ公表スベシ

常設中央委員會ハ本條約ニ依リ其ノ受領スル統計及他ノ情報ガ投機者ノ行動ヲ容易ナラシメ又ハ締約國ノ正當ナル商業ヲ阻害スルガ如キ方法ニ依リ公表セラレザルベキコトヲ確保スル爲一切ノ必要ナル措置ヲ執ルベシ

第六章　行政規定

第十五條

締約國ハ其ノ領域内ニ於テ本條約ノ規定ヲ實施スル爲ニ一切ノ必要ナル立法上又ハ他ノ措置ヲ執ルベシ

締約國ハ既ニ設置シタルニ非ザレバ左記目的ノ爲特別ノ行政機關ヲ設置スベシ

(イ)　本條約ノ規定ヲ適用スルコト

(ロ)　藥品取引ヲ規律シ、監視シ及取締ルコト

措又の施本
置は立の条
他法た約
の上め実

it thinks it unnecessary, of any explanations given or required in accordance with the preceding paragraph and any observations which the Board may desire to make in respect of any such explanation or request for an explanation.

The Permanent Central Board shall take all necessary measures to ensure that the statistics and other information which it receives under this Convention shall not be made public in such a manner as to facilitate the operations of speculators or to injure the legitimate commerce of any High Contracting Party.

Chapter VI.—Administrative Provisions.

Article 15.

The High Contracting Parties shall take all necessary legislative or other measures in order to give effect within their territories to the provisions of this Convention.

The High Contracting Parties shall, if they have not already done so, create a special administration for the purpose of:

(*a*) Applying the provisions of the present Convention;

(*b*) Regulating, supervising and controlling the trade in the drugs;

(ハ) 薬品中毒癖ノ蔓延ヲ防止シ及不正取引ヲ禁遏スル為一切ノ有用ナル措置ヲ執ルコトニ依リ中毒癖撲滅運動ヲ行フコト

第十六條

一　各締約國ハ左記ニ對シ嚴重ナル監視ヲ行フベシ

(イ) 薬品ノ製造若ハ轉換又ハ他ノ目的ノ為各製造業者ノ保有スル原料及既製薬品ノ數量

(ロ) 製産セラレタル薬品又ハ薬品ヲ含有スル製剤ノ數量

(ハ) 右製産セラレタル薬品及製剤ノ處分特ニ工場ヨリノ引渡

二　締約國ハ市場ノ情況ヲ考慮シタル上事業ノ經濟的經營ニ必要ナル數量ヲ超過スル原料ノ數量ノ製造業者ノ手許ニ於ケル蓄積ヲ許サザルベシ製造業者ノ手許ニ保有セラルル原料ノ如何ナル時ニ於ケル數量モ右製造業者ガ爾後ノ六月間ノ製造ニ要スル數量ヲ超過セザルベシ但シ政府ガ充分ナル調査ノ後例外的事情ニ依リ追加數量ノ蓄積ヲ正當ナリト認ムルトキハ

締約國の製造原料すべき積重なる監視を行うも

(c) Organising the campaign against drug addiction, by taking all useful steps to prevent its development and to suppress the illicit traffic.

Article 16.

1. Each High Contracting Party shall exercise a strict supervison over:

(a) The amounts of raw material and manufactured drugs in the possession of each manufacturer for the purpose of the manufacture or conversion of any of the drugs or otherwise;

(b) The quantities of the drugs or preparations containing the drugs produced;

(c) The disposal of the drugs and preparations so produced with especial reference to deliveries from the factories.

2. No High Contracting Party shall allow the accumulation in the possession of any manufacturer of quantities of raw materials in excess of those required for the economic conduct of business, having regard to the prevailing market conditions. The amounts of raw material in the possession of any manufacturer at any one time shall not exceed the amounts required by that manufacturer for manufacture during the ensuing six